Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free BNR Stock Alerts

Burning Rock Biotech (BNR) Competitors

Burning Rock Biotech logo
$8.37 +0.29 (+3.59%)
Closing price 06/30/2026 03:59 PM Eastern
Extended Trading
$8.60 +0.24 (+2.81%)
As of 06/30/2026 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BNR vs. SBC, LFMD, BDSX, XGN, and PARK

Should you buy Burning Rock Biotech stock or one of its competitors? MarketBeat compares Burning Rock Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Burning Rock Biotech include SBC Medical Group (SBC), LifeMD (LFMD), Biodesix (BDSX), Exagen (XGN), and Park Dental Partners (PARK). These companies are all part of the "healthcare" industry.

How does Burning Rock Biotech compare to SBC Medical Group?

Burning Rock Biotech (NASDAQ:BNR) and SBC Medical Group (NASDAQ:SBC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

SBC Medical Group has higher revenue and earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock Biotech$77.16M1.14-$7.92M-$0.82N/A
SBC Medical Group$173.61M1.82$50.99M$0.397.90

SBC Medical Group has a net margin of 24.09% compared to Burning Rock Biotech's net margin of -11.57%. SBC Medical Group's return on equity of 15.90% beat Burning Rock Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Burning Rock Biotech-11.57% -10.98% -7.33%
SBC Medical Group 24.09%15.90%11.61%

In the previous week, Burning Rock Biotech and Burning Rock Biotech both had 1 articles in the media. Burning Rock Biotech's average media sentiment score of 1.89 equaled SBC Medical Group'saverage media sentiment score.

Company Overall Sentiment
Burning Rock Biotech Very Positive
SBC Medical Group Very Positive

Burning Rock Biotech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

SBC Medical Group has a consensus price target of $8.50, indicating a potential upside of 175.97%. Given SBC Medical Group's stronger consensus rating and higher probable upside, analysts clearly believe SBC Medical Group is more favorable than Burning Rock Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Burning Rock Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
SBC Medical Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 81.7% of SBC Medical Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

SBC Medical Group beats Burning Rock Biotech on 13 of the 14 factors compared between the two stocks.

How does Burning Rock Biotech compare to LifeMD?

Burning Rock Biotech (NASDAQ:BNR) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, LifeMD had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 2 mentions for LifeMD and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat LifeMD's score of 0.62 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Burning Rock Biotech Very Positive
LifeMD Positive

LifeMD has a consensus target price of $9.14, suggesting a potential upside of 122.13%. Given LifeMD's stronger consensus rating and higher possible upside, analysts plainly believe LifeMD is more favorable than Burning Rock Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Burning Rock Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
LifeMD
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

LifeMD has a net margin of 2.37% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat LifeMD's return on equity.

Company Net Margins Return on Equity Return on Assets
Burning Rock Biotech-11.57% -10.98% -7.33%
LifeMD 2.37%-150.88%-22.59%

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Comparatively, 17.2% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

LifeMD has higher revenue and earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock Biotech$77.16M1.14-$7.92M-$0.82N/A
LifeMD$194.05M1.03$14.35M$0.0582.32

Burning Rock Biotech has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, LifeMD has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

Summary

LifeMD beats Burning Rock Biotech on 11 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Biodesix?

Burning Rock Biotech (NASDAQ:BNR) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, Biodesix had 2 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for Biodesix and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat Biodesix's score of 1.79 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Burning Rock Biotech Very Positive
Biodesix Very Positive

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Comparatively, 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Burning Rock Biotech has a net margin of -11.57% compared to Biodesix's net margin of -33.26%. Burning Rock Biotech's return on equity of -10.98% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Burning Rock Biotech-11.57% -10.98% -7.33%
Biodesix -33.26%-2,101.40%-35.65%

Burning Rock Biotech has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Burning Rock Biotech has higher earnings, but lower revenue than Biodesix. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock Biotech$77.16M1.14-$7.92M-$0.82N/A
Biodesix$88.50M2.64-$35.26M-$4.06N/A

Biodesix has a consensus price target of $28.33, indicating a potential upside of 25.65%. Given Biodesix's stronger consensus rating and higher possible upside, analysts plainly believe Biodesix is more favorable than Burning Rock Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Burning Rock Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Biodesix
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

Summary

Burning Rock Biotech beats Biodesix on 9 of the 17 factors compared between the two stocks.

How does Burning Rock Biotech compare to Exagen?

Exagen (NASDAQ:XGN) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Burning Rock Biotech has a net margin of -11.57% compared to Exagen's net margin of -29.49%. Burning Rock Biotech's return on equity of -10.98% beat Exagen's return on equity.

Company Net Margins Return on Equity Return on Assets
Exagen-29.49% -94.37% -28.96%
Burning Rock Biotech -11.57%-10.98%-7.33%

Burning Rock Biotech has higher revenue and earnings than Exagen. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exagen$66.57M1.69-$19.95M-$0.89N/A
Burning Rock Biotech$77.16M1.14-$7.92M-$0.82N/A

75.3% of Exagen shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Exagen currently has a consensus target price of $9.11, indicating a potential upside of 95.94%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than Burning Rock Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exagen
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90
Burning Rock Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Exagen has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

In the previous week, Exagen had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 2 mentions for Exagen and 1 mentions for Burning Rock Biotech. Exagen's average media sentiment score of 1.93 beat Burning Rock Biotech's score of 1.89 indicating that Exagen is being referred to more favorably in the media.

Company Overall Sentiment
Exagen Very Positive
Burning Rock Biotech Very Positive

Summary

Exagen beats Burning Rock Biotech on 10 of the 17 factors compared between the two stocks.

How does Burning Rock Biotech compare to Park Dental Partners?

Burning Rock Biotech (NASDAQ:BNR) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

30.0% of Burning Rock Biotech shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by insiders. Comparatively, 10.6% of Park Dental Partners shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Park Dental Partners had 2 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for Park Dental Partners and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat Park Dental Partners' score of 1.12 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Burning Rock Biotech Very Positive
Park Dental Partners Positive

Park Dental Partners has a consensus price target of $21.75, suggesting a potential upside of 0.93%. Given Park Dental Partners' stronger consensus rating and higher possible upside, analysts clearly believe Park Dental Partners is more favorable than Burning Rock Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Burning Rock Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Park Dental Partners
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
2 Strong Buy rating(s)
2.75

Park Dental Partners has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Park Dental Partners' return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Burning Rock Biotech-11.57% -10.98% -7.33%
Park Dental Partners N/A N/A N/A

Park Dental Partners has higher revenue and earnings than Burning Rock Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock Biotech$77.16M1.14-$7.92M-$0.82N/A
Park Dental Partners$244.49M0.40-$360KN/AN/A

Summary

Park Dental Partners beats Burning Rock Biotech on 9 of the 13 factors compared between the two stocks.

Get Burning Rock Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for BNR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BNR vs. The Competition

Export
MetricBurning Rock BiotechTechnology Services IndustryBusiness SectorNASDAQ Exchange
Market Cap$84.99M$4.22B$6.83B$12.45B
Dividend YieldN/A2.09%3.16%6.16%
P/E Ratio-10.2142.4330.2624.87
Price / Sales1.1447.80364.40102.84
Price / CashN/A37.0523.5658.59
Price / Book1.154.755.896.54
Net Income-$7.92M$31.79M$203.69M$336.70M
7 Day Performance-1.76%0.90%0.86%2.88%
1 Month Performance-4.12%-10.15%-4.57%0.64%
1 Year Performance161.56%21.52%26.62%31.34%

Burning Rock Biotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BNR
Burning Rock Biotech
1.1455 of 5 stars		$8.37
+3.6%		N/A+164.0%$84.99M$77.16MN/A1,390
SBC
SBC Medical Group
4.1622 of 5 stars		$3.07
+4.1%		$8.50
+176.9%		-33.6%$302.60M$169.34M7.87N/A
LFMD
LifeMD
2.6892 of 5 stars		$4.55
+5.6%		$9.14
+100.9%		-69.8%$208.45M$193.33M91.02230
BDSX
Biodesix
4.1616 of 5 stars		$19.16
+10.4%		$26.50
+38.3%		+299.5%$179.68M$96.10MN/A220
XGN
Exagen
4.3189 of 5 stars		$4.36
-1.4%		$9.25
+112.2%		-33.4%$106.79M$66.57MN/A220

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BNR) was last updated on 7/1/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel